Gilead combs Shoreline for NK cell therapies in $2.3bn allianceGilead Sciences’ cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging Share XGilead combs Shoreline for NK cell therapies in $2.3bn alliancehttps://pharmaphorum.com/news/gilead-combs-shoreline-for-nk-cell-therapies-in-2-3bn-alliance/
Catamaran joins the CAR-NK fleet, raising $42m in first roundCatamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its Share XCatamaran joins the CAR-NK fleet, raising $42m in first roundhttps://pharmaphorum.com/news/catamaran-joins-the-car-nk-fleet-raising-42m-in-first-round/
